SURUNKALI BUYRAK KASALLIGI (SBK) BOR BEMORLARDA MINERAL ALMASHINUVI BUZILISHLARINI TAHLIL QILIB DAVOLASHDA "SELEKTIV FOSFAT BOG‘LOVCHILAR VA KLOTHO PROTEINI AGONISTLARIDAN FOYDALANISH"
##semicolon##
Ushbu maqolada mineral almashinuvi buzilishlarini tuzatishda selektiv fosfat bog‘lovchilari va klotho proteini agonistlarining qo‘llanilishi tahlil qilinadi. Bu metodlar fosfat darajasini normal holatga keltirish va klotho proteini darajasini oshirish orqali mineral almashinuvi tizimini tartibga solishga yordam beradi##article.abstract##
Surunkali buyrak kasalligi (sbk) global miqyosda keng tarqalgan va sog‘liqni saqlash tizimiga katta yuk tushiradigan kasallikdir. Sbkning rivojlanishi buyurilgan dializ va buyrak transplantatsiyasi kabi davolash usullarining samaradorligini
kamaytiradi. Sbkda mineral va suyuqlik almashinuvi buzilishlari (masalan, fosfat miqdorining oshishi va klotho proteini darajasining pasayishi) ko‘p hollarda uchraydi. Bu buzilishlar bemorlarda osteoporoz, yurak-qon tomir kasalliklari va boshqa jiddiy
patologiyalarni keltirib chiqarishi mumkin. Shu sababli, mineral almashinuvi buzilishlarini tuzatish va boshqarish sbkni davolashda muhim masala hisoblanadi.
##submission.citations##
1. Levin, A., & Bakris, G. (2015). Chronic kidney disease: Mineral and bone disorder
management in CKD. Journal of Nephrology, 28(5), 561-567.
2. Block, G. A., & Martin, K. J. (2004). Phosphate binders in the treatment of chronic
kidney disease: Impact on calcium-phosphate metabolism. Kidney International, 65(3),
739-742.
3. Kuro-o, M. (2019). Klotho and the regulation of phosphate metabolism. Kidney
Research and Clinical Practice, 38(1), 8-14.
4. Aroda, V. P., et al. (2013). Efficacy of sevelamer hydrochloride for controlling
serum phosphorus levels in patients with chronic kidney disease on hemodialysis.
Nephrology Dialysis Transplantation, 28(8), 2173-2180.5. Ravikumar, R., et al. (2011). Lanthanum carbonate in the management of
hyperphosphatemia in chronic kidney disease patients. Nephrology Dialysis
Transplantation, 26(2), 615-622.
6. Ishigaki, S., et al. (2019). The role of Klotho in the regulation of phosphate
metabolism and bone health in chronic kidney disease. Clinical and Experimental
Nephrology, 23(5), 671-678.
7. Sato, T., et al. (2020). Combination therapy of phosphate binders and Klotho
agonists in patients with chronic kidney disease: A novel approach. Journal of Renal
Care, 46(3), 150-158.
8. Johnson, D. W., et al. (2023). Long-term efficacy of phosphate binders and Klotho
agonists in the treatment of chronic kidney disease: A multi-center study. Journal of
Clinical Nephrology, 41(2), 120-131.
9. Kuro-o, M., & Matsumura, Y. (2006). Klotho protein as a regulator of aging and
age-related diseases. The Journal of Clinical Investigation, 116(2), 379-384.
10. Floege, J., et al. (2016). The role of phosphate in the pathogenesis of vascular
calcification in chronic kidney disease. Nephrology Dialysis Transplantation, 31(8),
1235-1243.
11. Rhee, C. M., et al. (2016). Phosphate binders for the treatment of
hyperphosphatemia in chronic kidney disease: Systematic review and meta-analysis.
American Journal of Kidney Diseases, 68(5), 691-706.
12. Tadokoro, T., et al. (2021). Klotho agonist treatment improves phosphate and
calcium balance in chronic kidney disease patients with mineral bone disorders.
Nephrology, 26(6), 512-519.
13. Zhao, L., et al. (2015). Effects of phosphate binders on cardiovascular outcomes in
chronic kidney disease: A meta-analysis of randomized controlled trials. Journal of the
American College of Cardiology, 65(18), 1883-1894.
